

UMBRELLA

Focused
Cardiology Forums

HEART & STROKE

CASE-BASED DISCUSSION

4th Session

**Antithrombotic therapy for secondary
prevention of stroke**

LEARNING OBJECTIVES



abidi
Cardio Thrombosis

شركة سینازن
CinnaGen

Ronak
Pharmaceutical Co.

ACTOVERCO
Together for a healthy future

Antithrombotic therapy for secondary prevention of stroke

LEARNING OBJECTIVES

- Early Antithrombotic treatment in TIA/CVA (First days)
 - Anti-platelet therapy: agents of choice
 - Anti-coagulant therapy: choosing the agent and the duration of use
- Chronic Antithrombotic therapy (including ESUS)
 - Indications for DAPT
 - Choosing between P2Y12 inhibitors and the duration of therapy
 - Extended DAPT duration: indication & the combination of choice
 - Choosing the best Monotherapy strategy
 - Indications for DPI

Antithrombotic therapy for secondary prevention of stroke

LEARNING OBJECTIVES

- CVA/TIA in patient with Atrial Fibrillation
 - Antithrombotic therapy after CVA/TIA
 - choosing between oral anticoagulants (VKA/NOACs)
 - Indication for antiplatelet therapy
- Antithrombotic therapy after PCI in patients with a history of embolic stroke
 - Oral anticoagulant and antiplatelet of choice: optimal duration

Antithrombotic therapy for secondary prevention of stroke

LEARNING OBJECTIVES

- Choosing the antithrombotic therapy in special situations:
 - After carotid revascularization: CAS/CEA
 - Antiplatelet therapy failure
 - Cerebral and cervical artery dissection